San Diego-based Amplyx Pharmaceuticals announced Wednesday that the company has closed on a $40.5 million Series B financing.
The round was led by RiverVest Venture Partners, and included investments by New Enterprise Associates, BioMed Ventures and individual investors.
Amplyx, a current tenant of Johnson and Johnson Innovation’s incubator JLABS, will use the funding to advance the clinical development of APX001, the company’s broad-spectrum antifungal agent to treat life-threatening fungal infections.
